Vaccines for epidemic infections and the role of CEPI

References

• Plotkin SA, Mahmoud AA, Farrar J. Establishing a Global Vaccine-Development Fund. N Engl J Med 2015; 373(4:297-300; PMID:26200974; http://dx.doi.org/10.1056/NEJMp1506820
   PubMed Web of Science ®Google Scholar
• Abushouk AI, Negida A, Ahmed H. An updated review of Zika virus. J Clin Virol 2016; 84:53-8; http://dx.doi.org/10.1016/j.jcv.2016.09.012
   PubMed Web of Science ®Google Scholar
• Pierson TC, Graham BS. Zika virus: Immunity and vaccine development. Cell 2016; 167(3):625-31; PMID:27693357; http://dx.doi.org/10.1016/j.cell.2016.09.020
   PubMed Web of Science ®Google Scholar
• Pronker ES, Weenen TC, Commandeur HR, Osterhaus AD, Claassen HJ. The gold industry standard for risk and cost of drug and vaccine development revisited. Vaccine 2011; 29(35):5846-9; PMID:21722688; http://dx.doi.org/10.1016/j.vaccine.2011.06.051
   PubMed Web of Science ®Google Scholar
• MacNeil JR, Rubin L, Folaranmi T, Ortega-Sanchez IR, Patel M, Martin SW. Use of serogroup B meningococcal vaccines in adolescents and young adults: Recommendations of the advisory committee on immunization practices, 2015. MMWR Morb Mortal Wkly Rep 2015; 64(41):1171-6; PMID:26492381; http://dx.doi.org/10.15585/mmwr.mm6441a3
   PubMed Web of Science ®Google Scholar
• MacNeil JR, Bennett N, Farley MM, Harrison LH, Lynfield R, Nichols M, Petit S, Reingold A, Schaffner W, Thomas A, et al. Epidemiology of infant meningococcal disease in the United States, 2006–2012. Pediatrics 2015; 135(2):e305-311; PMID:25583921; http://dx.doi.org/10.1542/peds.2014-2035
   PubMed Web of Science ®Google Scholar
• Kindhauser MK, Allen T, Frank V, Santhana RS, Dye C. Zika: the origin and spread of a mosquito-borne virus. Bull World Health Organ 2016; 94(9):675-686c; PMID:27708473; http://dx.doi.org/10.2471/BLT.16.171082
   PubMed Web of Science ®Google Scholar
• Gao F, Bailes E, Robertson DL, Chen Y, Rodenburg CM, Michael SF, Cummins LB, Arthur LO, Peeters M, Shaw GM, et al. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 1999; 397(6718):436-41; PMID:9989410; http://dx.doi.org/10.1038/17130
   PubMed Web of Science ®Google Scholar
• Donnelly CA, Fisher MC, Fraser C, Ghani AC, Riley S, Ferguson NM, Anderson RM. Epidemiological and genetic analysis of severe acute respiratory syndrome. Lancet Infect Dis 2004; 4(11):672-83; PMID:15522679; http://dx.doi.org/10.1016/S1473-3099(04)01173-9
   PubMed Web of Science ®Google Scholar
• Rottingen JA, Gouglas D, Feinberg M, Plotkin S, Raghavan KV, Witty A, Draghia-Akli R, Stoffels P, Piot P. New vaccines against epidemic infectious diseases. N Engl J Med 2017; 376:610-13; PMID:28099066; http://dx.doi.org/10.1056/NEJMp1613577
   PubMed Web of Science ®Google Scholar
• Ferraro B, Morrow MP, Hutnick NA, Shin TH, Lucke CE, Weiner DB. Clinical applications of DNA vaccines: current progress. Clin Infect Dis 2011; 53(3):296-302; PMID:21765081; http://dx.doi.org/10.1093/cid/cir334
   PubMed Web of Science ®Google Scholar
• Kramps T, Elbers K. Introduction to RNA Vaccines. Methods Mol Biol 2017; 1499:1-11. http://dx.doi.org/10.1007/978-1-4939-6481-9_1
   PubMedGoogle Scholar
• Geisbert TW, Feldmann H. Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis 2011; 204(Suppl 3):S1075-81; http://dx.doi.org/10.1093/infdis/jir349
   PubMed Web of Science ®Google Scholar
• Tangy F, Naim HY. Live attenuated measles vaccine as a potential multivalent pediatric vaccination vector. Viral Immunol 2005; 18(2):317-26; PMID:16035943; http://dx.doi.org/10.1089/vim.2005.18.317
   PubMed Web of Science ®Google Scholar
• Capone S, D'Alise AM, Ammendola V, Colloca S, Cortese R, Nicosia A, Folgori A. Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials. Expert Rev Vaccines 2013; 12(4):379-93; PMID:23560919; http://dx.doi.org/10.1586/erv.13.15
   PubMed Web of Science ®Google Scholar
• Altenburg AF, Kreijtz JH, de Vries RD, Song F, Fux R, Rimmelzwaan GF, Sutter G, Volz A. Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. Viruses 2014; 6(7):2735-61; PMID:25036462; http://dx.doi.org/10.3390/v6072735
   PubMed Web of Science ®Google Scholar
• Martins KA, Jahrling PB, Bavari S, Kuhn JH. Ebola virus disease candidate vaccines under evaluation in clinical trials. Expert Rev Vaccines 2016; 15(9):1101-12; PMID:27160784; http://dx.doi.org/10.1080/14760584.2016.1187566
   PubMed Web of Science ®Google Scholar
• Anthony SM, Bradfute SB. Filoviruses: One of these things is (not) like the other. Viruses 2015; 7(10):5172-90; PMID:26426036; http://dx.doi.org/10.3390/v7102867
   PubMed Web of Science ®Google Scholar
• Pavot V. Ebola virus vaccines: Where do we stand? Clin Immunol 2016; 173:44-9; http://dx.doi.org/10.1016/j.clim.2016.10.016
   PubMed Web of Science ®Google Scholar
• Modjarrad K. MERS-CoV vaccine candidates in development: The current landscape. Vaccine 2016; 34(26):2982-7; PMID:27083424; http://dx.doi.org/10.1016/j.vaccine.2016.03.104
   PubMed Web of Science ®Google Scholar
• Ma C, Wang L, Tao X, Zhang N, Yang Y, Tseng CT, Li F, Zhou Y, Jiang S, Du L. Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments–the importance of immunofocusing in subunit vaccine design. Vaccine 2014; 32(46):6170-6; PMID:25240756; http://dx.doi.org/10.1016/j.vaccine.2014.08.086
   PubMed Web of Science ®Google Scholar
• Coleman CM, Sisk JM, Halasz G, Zhong J, Beck SE, Matthews KL, Venkataraman T, Rajagopalan S, Kyratsous CA, Frieman MB. CD8+ T cells and macrophages regulate pathogenesis in a mouse model of Middle East respiratory syndrome. J Virol 2017; 91(1); http://dx.doi.org/10.1128/jvi.01825-16
   Google Scholar
• Wang C, Zheng X, Gai W, Wong G, Wang H, Jin H, Feng N, Zhao Y, Zhang W, Li N, et al. Novel chimeric virus-like particles vaccine displaying MERS-CoV receptor-binding domain induce specific humoral and cellular immune response in mice. Antiviral Res 2017; 140:55-61; http://dx.doi.org/10.1016/j.antiviral.2016.12.019
   Google Scholar
• Liu WJ, Zhao M, Liu K, Xu K, Wong G, Tan W, Gao GF. T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV. Antiviral Res 2017; 137:82-92; http://dx.doi.org/10.1016/j.antiviral.2016.11.006
   PubMed Web of Science ®Google Scholar
• Papaneri AB, Johnson RF, Wada J, Bollinger L, Jahrling PB, Kuhn JH. Middle East respiratory syndrome: obstacles and prospects for vaccine development. Expert Rev Vaccines 2015; 14(7):949-62; PMID:25864502; http://dx.doi.org/10.1586/14760584.2015.1036033
   PubMed Web of Science ®Google Scholar
• Muthumani K, Falzarano D, Reuschel EL, Tingey C, Flingai S, Villarreal DO, Wise M, Patel A, Izmirly A, Aljuaid A, et al. A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci Transl Med 2015; 7(301):301ra132; PMID:26290414; http://dx.doi.org/10.1126/scitranslmed.aac7462
   PubMed Web of Science ®Google Scholar
• Haagmans BL, van den Brand JM, Raj VS, Volz A, Wohlsein P, Smits SL, Schipper D, Bestebroer TM, Okba N, Fux R, et al. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. Science 2016; 351(6268):77-81; PMID:26678878; http://dx.doi.org/10.1126/science.aad1283
   PubMed Web of Science ®Google Scholar
• Excler J-L, Delvecchio CJ, Wiley RE, Williams M, Yoon I-K, Modjarrad K, Boujelal M, Moorthy VS, Hersi AS, Kim JH, et al. Toward developing a preventive MERS-CoV vaccine-Report from a workshop organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute, Riyadh, Saudi Arabia, November 14-15, 2015. Emerg Infect Dis 2016; 22(8); http://dx.doi.org/10.3201/eid2208.160229
   Google Scholar
• Satterfield BA, Dawes BE, Milligan GN. Status of vaccine research and development of vaccines for Nipah virus. Vaccine 2016; 34(26):2971-5; PMID:26973068; http://dx.doi.org/10.1016/j.vaccine.2015.12.075
   PubMed Web of Science ®Google Scholar
• Broder CC, Weir DL, Reid PA. Hendra virus and Nipah virus animal vaccines. Vaccine 2016; 34(30):3525-34; PMID:27154393; http://dx.doi.org/10.1016/j.vaccine.2016.03.075
   PubMed Web of Science ®Google Scholar
• Prescott J, DeBuysscher BL, Feldmann F, Gardner DJ, Haddock E, Martellaro C, Scott D, Feldmann H. Single-dose live-attenuated vesicular stomatitis virus-based vaccine protects African green monkeys from Nipah virus disease. Vaccine 2015; 33(24):2823-9; PMID:25865472; http://dx.doi.org/10.1016/j.vaccine.2015.03.089
   PubMed Web of Science ®Google Scholar
• Yoneda M, Georges-Courbot MC, Ikeda F, Ishii M, Nagata N, Jacquot F, Raoul H, Sato H, Kai C. Recombinant measles virus vaccine expressing the Nipah virus glycoprotein protects against lethal Nipah virus challenge. PLoS One 2013; 8(3):e58414; PMID:23516477; http://dx.doi.org/10.1371/journal.pone.0058414
   PubMed Web of Science ®Google Scholar
• Ambrosio A, Saavedra M, Mariani M, Gamboa G, Maiza A. Argentine hemorrhagic fever vaccines. Hum Vaccin 2011; 7(6):694-700; PMID:21451263; http://dx.doi.org/10.4161/hv.7.6.15198
   PubMed Web of Science ®Google Scholar
• Emmerich P, Gunther S, Schmitz H. Strain-specific antibody response to Lassa virus in the local population of west Africa. J Clin Virol 2008; 42(1):40-44; PMID:18164653; http://dx.doi.org/10.1016/j.jcv.2007.11.019
   PubMed Web of Science ®Google Scholar
• McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, Johnson KM, Elliott LH, Belmont-Williams R. Lassa fever. Effective therapy with ribavirin. N Engl J Med 1986; 314(1):20-6; PMID:3940312; http://dx.doi.org/10.1056/NEJM198601023140104
   PubMed Web of Science ®Google Scholar
• Lukashevich IS. Advanced vaccine candidates for Lassa fever. Viruses 2012; 4(11):2514-57; PMID:23202493; http://dx.doi.org/10.3390/v4112514
   PubMed Web of Science ®Google Scholar
• Safronetz D, Mire C, Rosenke K, Feldmann F, Haddock E, Geisbert T, Feldmann H. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses. PLoS Negl Trop Dis 2015; 9(4):e0003736; PMID:25884628; http://dx.doi.org/10.1371/journal.pntd.0003736
   PubMed Web of Science ®Google Scholar
• Zeller H, Van Bortel W, Sudre B. Chikungunya: Its history in africa and asia and its spread to new regions in 2013–2014. J Infect Dis 2016; 214(suppl 5):S436-40; PMID:27920169; http://dx.doi.org/10.1093/infdis/jiw391
   PubMed Web of Science ®Google Scholar
• Morens DM, Fauci AS. Meeting the challenge of epidemic chikungunya. J Infect Dis 2016; 214(suppl 5):S434-5; PMID:27920168; http://dx.doi.org/10.1093/infdis/jiw291
   PubMedGoogle Scholar
• Thiberville SD, Moyen N, Dupuis-Maguiraga L, Nougairede A, Gould EA, Roques P, de Lamballerie X. Chikungunya fever: epidemiology, clinical syndrome, pathogenesis and therapy. Antiviral Res 2013; 99(3):345-70; PMID:23811281; http://dx.doi.org/10.1016/j.antiviral.2013.06.009
   PubMed Web of Science ®Google Scholar
• Muthumani K, Block P, Flingai S, Muruganantham N, Chaaithanya IK, Tingey C, Wise M, Reuschel EL, Chung C, Muthumani A, et al. Rapid and long-term immunity elicited by DNA-encoded antibody prophylaxis and DNA vaccination against chikungunya virus. J Infect Dis 2016; 214(3):369-78; PMID:27001960; http://dx.doi.org/10.1093/infdis/jiw111
   PubMed Web of Science ®Google Scholar
• Erasmus JH, Auguste AJ, Kaelber JT, Luo H, Rossi SL, Fenton K, Leal G, Kim DY, Chiu W, Wang T, et al. A chikungunya fever vaccine utilizing an insect-specific virus platform. Nat Med 2017; 23(2):192-199; http://dx.doi.org/10.1038/nm.4253
   Google Scholar
• Schwameis M, Buchtele N, Wadowski PP, Schoergenhofer C, Jilma B. Chikungunya vaccines in development. Hum Vaccin Immunother 2016; 12(3):716-31; PMID:26554522; http://dx.doi.org/10.1080/21645515.2015.1101197
   PubMed Web of Science ®Google Scholar
• Erasmus JH, Rossi SL, Weaver SC. Development of vaccines for chikungunya fever. J Infect Dis 2016; 214(suppl 5):S488-96; PMID:27920179; http://dx.doi.org/10.1093/infdis/jiw271
   PubMedGoogle Scholar
• DeZure AD, Berkowitz NM, Graham BS, Ledgerwood JE. Whole-inactivated and virus-like particle vaccine strategies for chikungunya virus. J Infect Dis 2016; 214(suppl 5):S497-9; PMID:27920180; http://dx.doi.org/10.1093/infdis/jiw352
   PubMedGoogle Scholar
• Ramsauer K, Tangy F. Chikungunya virus vaccines: Viral vector-based approaches. J Infect Dis 2016; 214(suppl 5):S500-5; PMID:27920181; http://dx.doi.org/10.1093/infdis/jiw369
   PubMedGoogle Scholar
• Metz SW, Pijlman GP. Production of chikungunya virus-like particles and subunit vaccines in insect cells. Methods Mol Biol 2016; 1426:297-309; PMID:27233282; doi: 10.1007/978-1-4939-3618-2_27
   PubMedGoogle Scholar
• Smalley C, Erasmus JH, Chesson CB, Beasley DW. Status of research and development of vaccines for chikungunya. Vaccine 2016; 34(26):2976-81; PMID:27026149; http://dx.doi.org/10.1016/j.vaccine.2016.03.076
   PubMed Web of Science ®Google Scholar
• Akahata W, Yang ZY, Andersen H, Sun S, Holdaway HA, Kong WP, Lewis MG, Higgs S, Rossmann MG, Rao S, et al. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med 2010; 16(3):334-8; PMID:20111039; http://dx.doi.org/10.1038/nm.2105
   PubMed Web of Science ®Google Scholar
• Goo L, Dowd KA, Lin TY, Mascola JR, Graham BS, Ledgerwood JE, Pierson TC. A virus-like particle vaccine elicits broad neutralizing antibody responses in humans to all chikungunya virus genotypes. J Infect Dis 2016; 214(10):1487-91; PMID:27655868; http://dx.doi.org/10.1093/infdis/jiw431
   PubMed Web of Science ®Google Scholar
• Ramsauer K, Schwameis M, Firbas C, Mullner M, Putnak RJ, Thomas SJ, Desprès P, Tauber E, Jilma B, Tangy F. Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect Dis 2015; 15(5):519-27; PMID:25739878; http://dx.doi.org/10.1016/S1473-3099(15)70043-5
   PubMed Web of Science ®Google Scholar
• Yoon IK, Alera MT, Lago CB, Tac-An IA, Villa D, Fernandez S, Thaisomboonsuk B, Klungthong C, Levy JW, Velasco JM, et al. High rate of subclinical chikungunya virus infection and association of neutralizing antibody with protection in a prospective cohort in the Philippines. PLoS Negl Trop Dis 2015; 9(5):e0003764; PMID:25951202; http://dx.doi.org/10.1371/journal.pntd.0003764
   PubMed Web of Science ®Google Scholar
• Poore EA, Slifka DK, Raue HP, Thomas A, Hammarlund E, Quintel BK, Torrey LL, Slifka AM, Richner JM, Dubois ME, et al. Pre-clinical development of a hydrogen peroxide-inactivated West Nile virus vaccine. Vaccine 2017; 35(2):283-92; PMID:27919629; http://dx.doi.org/10.1016/j.vaccine.2016.11.080
   PubMed Web of Science ®Google Scholar
• Chancey C, Grinev A, Volkova E, Rios M. The global ecology and epidemiology of West Nile virus. Biomed Res Int 2015; 2015:376230; PMID:25866777; http://dx.doi.org/10.1155/2015/376230
   PubMed Web of Science ®Google Scholar
• Murray KO, Garcia MN, Rahbar MH, Martinez D, Khuwaja SA, Arafat RR, Rossmann S. Survival analysis, long-term outcomes, and percentage of recovery up to 8 years post-infection among the Houston West Nile virus cohort. PLoS One 2014; 9(7):e102953; PMID:25054656; http://dx.doi.org/10.1371/journal.pone.0102953
   PubMed Web of Science ®Google Scholar
• Weatherhead JE, Miller VE, Garcia MN, Hasbun R, Salazar L, Dimachkie MM, Murray KO. Long-term neurological outcomes in West Nile virus-infected patients: an observational study. Am J Trop Med Hyg 2015; 92(5):1006-12; PMID:25802426; http://dx.doi.org/10.4269/ajtmh.14-0616
   PubMed Web of Science ®Google Scholar
• Higgs S, Schneider BS, Vanlandingham DL, Klingler KA, Gould EA. Nonviremic transmission of West Nile virus. Proc Natl Acad Sci U S A 2005; 102(25):8871-4; PMID:15951417; http://dx.doi.org/10.1073/pnas.0503835102
   PubMed Web of Science ®Google Scholar
• Gire SK, Goba A, Andersen KG, Sealfon RS, Park DJ, Kanneh L, Jalloh S, Momoh M, Fullah M, Dudas G, et al. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science 2014; 345(6202):1369-72; PMID:25214632; http://dx.doi.org/10.1126/science.1259657
   PubMed Web of Science ®Google Scholar
• Arinaminpathy N, McLean AR. Evolution and emergence of novel human infections. Proc Biol Sci 2009; 276(1675):3937-43; PMID:19692402; http://dx.doi.org/10.1098/rspb.2009.1059
   PubMed Web of Science ®Google Scholar
• Sharp PM, Hahn BH. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med 2011; 1(1):a006841; PMID:22229120; http://dx.doi.org/10.1101/cshperspect.a006841
   PubMed Web of Science ®Google Scholar
• Han HJ, Wen HL, Zhou CM, Chen FF, Luo LM, Liu JW, Yu XJ. Bats as reservoirs of severe emerging infectious diseases. Virus Res 2015; 205:1-6; PMID:25997928; http://dx.doi.org/10.1016/j.virusres.2015.05.006
   PubMed Web of Science ®Google Scholar
• Wolfe ND, Dunavan CP, Diamond J. Origins of major human infectious diseases. Nature 2007; 447(7142):279-83; PMID:17507975; http://dx.doi.org/10.1038/nature05775
   PubMed Web of Science ®Google Scholar
• Morse SS, Mazet JA, Woolhouse M, Parrish CR, Carroll D, Karesh WB, Zambrana-Torrelio C, Lipkin WI, Daszak P. Prediction and prevention of the next pandemic zoonosis. Lancet 2012; 380(9857):1956-65; PMID:23200504; http://dx.doi.org/10.1016/S0140-6736(12)61684-5
   PubMed Web of Science ®Google Scholar
• Woolhouse ME, Rambaut A, Kellam P. Lessons from Ebola: Improving infectious disease surveillance to inform outbreak management. Sci Transl Med 2015; 7(307):307-5; http://dx.doi.org/10.1126/scitranslmed.aab0191
   Web of Science ®Google Scholar
• Woolhouse ME, Brierley L, McCaffery C, Lycett S. Assessing the epidemic potential of RNA and DNA viruses. Emerg Infect Dis 2016; 22(12):2037-44; PMID:27869592; http://dx.doi.org/10.3201/eid2212.160123
   PubMed Web of Science ®Google Scholar
• Teh CS, Chua KH, Thong KL. Paratyphoid fever: splicing the global analyses. Int J Med Sci 2014; 11(7):732-41; PMID:24904229; http://dx.doi.org/10.7150/ijms.7768
   PubMed Web of Science ®Google Scholar
• Gillespie PM, Beaumier CM, Strych U, Hayward T, Hotez PJ, Bottazzi ME. Status of vaccine research and development of vaccines for leishmaniasis. Vaccine 2016; 34(26):2992-5; PMID:26973063; http://dx.doi.org/10.1016/j.vaccine.2015.12.071
   PubMed Web of Science ®Google Scholar
• Merrifield M, Hotez PJ, Beaumier CM, Gillespie P, Strych U, Hayward T, Bottazzi ME. Advancing a vaccine to prevent human schistosomiasis. Vaccine 2016; 34(26):2988-91; PMID:27036511; http://dx.doi.org/10.1016/j.vaccine.2016.03.079
   PubMed Web of Science ®Google Scholar
• Ryan U, Zahedi A, Paparini A. Cryptosporidium in humans and animals-a one health approach to prophylaxis. Parasite Immunol 2016; 38(9):535-47; PMID:27454991; http://dx.doi.org/10.1111/pim.12350
   PubMed Web of Science ®Google Scholar